Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress

Sandeep Raj, Allison Bock, Sharmila Giri, Dilan Patel, Madiha Iqbal, Natalie Grover, Lori Leslie, Marcus Geer, Olalekan Oluwole, Boyu Hu, Grzegorz Nowakowski, Miguel-Angel Perales

Blood (2025) 146 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2025-3748

Published: 2025

Journal Articles

Autologous stem cell transplantation and real-world outcomes in angioimmunoblastic T-cell lymphoma: A national cohort study

Yu Tao, Ayo Falade, Richard Godby, Steven Hwang, N. Nora Bennani, Stephen Ansell, Grzegorz Nowakowski, Yucai Wang, Jihao Zhou

Blood (2025) 146 (Supplement 1): 3640.

https://doi.org/10.1182/blood-2025-3640

Published: 2025

Journal Articles

Lymphovision: A lymphoma-specialized foundation model for histology-based lymphoma classification and subtyping

Blood (2025) 146 (Supplement 1): 117.

https://doi.org/10.1182/blood-2025-117

Published: 2025

Journal Articles

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2025-4516

Published: 2025

Journal Articles

Anatomical localization-based analysis of de novo secondary cns lymphoma

Izel Okcu, Zhuo Li, Launia White, Yucai Wang, Patrick Johnston, Allison Rosenthal, Arushi Khurana, Urshila Durani, Jonas Paludo, Rebecca King, Thomas Witzig, Thomas Habermann, Grzegorz Nowakowski, Han Tun

Blood (2025) 146 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2025-3675

Published: 2025

Journal Articles

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era

Julia Wang, Steven Hwang, Urshila Durani, Gita Thanarajasingam, Arushi Khurana, Jonas Paludo, Yucai Wang, Grzegorz Nowakowski, Thomas Habermann, Thomas Witzig, Stephen Ansell, Jithma Abeykoon

Blood (2025) 146 (Supplement 1): 5399.

https://doi.org/10.1182/blood-2025-5399

Published: 2025

Journal Articles

Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma

Giuseppe Maiocco, Yoshito Nishimura, Guneet Janda, Yiqun Han, Urshila Durani, Grzegorz Nowakowski, Jonas Paludo, Stephen Ansell, Jithma Abeykoon

Blood (2025) 146 (Supplement 1): 5395.

https://doi.org/10.1182/blood-2025-5395

Published: 2025

Journal Articles

The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)

Blood (2025) 146 (Supplement 1): 518.

https://doi.org/10.1182/blood-2025-518

Published: 2025

Journal Articles

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Ayo Falade, Yu Tao, Olisaemeka Ogbue, Oluwatayo Adeoye, Ayodeji Johnson, Arushi Khurana, Jithma Abeykoon, Urshila Durani, Mazie Tsang, Allison Rosenthal, Talal Hilal, Javier Munoz, Patrick Johnston, Han Tun, Grzegorz Nowakowski, James Cerhan, Richard Godby, Yucai Wang, Jihao Zhou

Blood (2025) 146 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2025-4494

Published: 2025

Journal Articles

Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma

Stephen Smith, Suchitra Sundaram, Sharmila Giri, Andy Ness, Yucai Wang, Yifan Pang, Ajay Gopal, Emily Tatoian, Trenton Grossfeld, Ryan Lynch, Edus Warren, Grzegorz Nowakowski, Steven Park

Blood (2025) 146 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2025-3575

Published: 2025

Journal Articles

An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 5481.

https://doi.org/10.1182/blood-2025-5481

Published: 2025

Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3704.

https://doi.org/10.1182/blood-2025-3704

Published: 2025

Journal Articles

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Blood (2025) 146 (Supplement 1): 6312.

https://doi.org/10.1182/blood-2025-6312

Published: 2025

Journal Articles

Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic

Ayo Falade, Abiola Bolarinwa, Oluwatayo Adeoye, Muhammad Yousuf, Allison Rosenthal, Mazie Tsang, Madiha Iqbal, Daniel Lachance, Rebecca King, Yucai Wang, Micallef Ivana, Robert Spinner, Thomas Habermann, Grzegorz Nowakowski, Arushi Khurana, Patrick Johnston

Blood (2025) 146 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2025-6306

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos

Blood (2025) 146 (Supplement 1): 476.

https://doi.org/10.1182/blood-2025-476

Published: 2025

Journal Articles

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 473.

https://doi.org/10.1182/blood-2025-473

Published: 2025

Journal Articles

Bioflipi scores define distinct immune profiles in follicular lymphoma

Jordan Krull, Qin Ma, Emmanuel Contreras Guzman, Rebecca King, Andrew Feldman, Surendra Dasari, Diwakar Suresh, Jose Villasboas Bisneto, Matthew Maurer, Brian Link, Eric Hsi, Grzegorz Nowakowski, Thomas Habermann, Anne Novak, Melissa Larson, James Cerhan, Stephen Ansell, Patrizia Mondello

Blood (2025) 146 (Supplement 1): 5328.

https://doi.org/10.1182/blood-2025-5328

Published: 2025

Journal Articles

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Blood (2025) 146 (Supplement 1): 5448.

https://doi.org/10.1182/blood-2025-5448

Published: 2025

Journal Articles

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 <1% expression

Grzegorz Nowakowski, Rebecca King, Daniel Kearney, Nancy Bartlett, Jeong-A Kim, Isabelle Fleury, Luigina Mollica, Craig Portell, Christopher Yasenchak, Keenan Fenton, Christopher Hale, Diana Hubbard, Hailing Lu, Monica Patterson, Michelle Fanale, Evelyn Rustia, Uwe Hahn

Blood (2025) 146 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2025-1905

Published: 2025

Journal Articles

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Blood (2025) 146 (Supplement 1): 898.

https://doi.org/10.1182/blood-2025-898

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress

Autologous stem cell transplantation and real-world outcomes in angioimmunoblastic T-cell lymphoma: A national cohort study

Lymphovision: A lymphoma-specialized foundation model for histology-based lymphoma classification and subtyping

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Anatomical localization-based analysis of de novo secondary cns lymphoma

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era

Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma

The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma

An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Bioflipi scores define distinct immune profiles in follicular lymphoma

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 <1% expression

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only